Voyager Therapeutics’ (VYGR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report issued on Monday,Benzinga reports. HC Wainwright also issued estimates for Voyager Therapeutics’ Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($1.32) EPS, Q1 2027 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.26) EPS, Q3 2027 earnings at ($0.27) EPS, Q4 2027 earnings at ($0.25) EPS, FY2027 earnings at ($1.06) EPS, FY2028 earnings at ($1.17) EPS, FY2029 earnings at ($0.98) EPS and FY2030 earnings at ($0.55) EPS.

VYGR has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Monday, July 13th. Wall Street Zen cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.50.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $3.20 on Monday. Voyager Therapeutics has a twelve month low of $2.93 and a twelve month high of $5.55. The firm has a market cap of $197.18 million, a PE ratio of -1.78 and a beta of 1.31. The firm’s 50 day moving average price is $3.38 and its two-hundred day moving average price is $3.72.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Thursday, August 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.08. Voyager Therapeutics had a negative net margin of 312.63% and a negative return on equity of 54.82%. The company had revenue of $3.17 million during the quarter, compared to analyst estimates of $4.52 million. Equities analysts anticipate that Voyager Therapeutics will post -1.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Voyager Therapeutics

Several institutional investors have recently bought and sold shares of VYGR. AQR Capital Management LLC boosted its stake in shares of Voyager Therapeutics by 179.3% during the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock worth $1,674,000 after acquiring an additional 317,927 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Voyager Therapeutics during the 1st quarter valued at about $218,000. Acadian Asset Management LLC raised its stake in shares of Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after acquiring an additional 206,758 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Voyager Therapeutics by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock valued at $3,474,000 after acquiring an additional 11,929 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in Voyager Therapeutics by 5.1% in the 2nd quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock worth $430,000 after purchasing an additional 6,748 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors.

Key Stories Impacting Voyager Therapeutics

Here are the key news stories impacting Voyager Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts across multiple periods, including FY2026 to a loss of $1.32 per share from $1.61, FY2027 to a loss of $1.06 from $1.18, FY2028 to a loss of $1.17 from $1.63, FY2029 to a loss of $0.98 from $1.38, and FY2030 to a loss of $0.55 from $0.94. The firm also improved its estimates for the third and fourth quarters of 2026 and each quarter of 2027, indicating expectations for narrower losses than previously projected. HC Wainwright maintained its “Buy” rating on Voyager. HC Wainwright Reaffirms Buy Rating for Voyager Therapeutics
• Neutral Sentiment: Short-interest data showed no measurable bearish positioning, reporting zero shares sold short as of August 11. However, the data also showed zero shares in the prior reporting period and a zero-day short-interest ratio, making the reported change unreliable and unlikely to be a meaningful trading catalyst.
• Negative Sentiment: Despite the forecast improvements, Voyager remains loss-making. The company’s current full-year consensus estimate is a loss of $1.39 per share, and its recent quarter included a $0.40-per-share loss and $3.17 million in revenue, below the $4.52 million analyst expectation. The stock’s market price of $3.20 is below its 50-day average of $3.38 and 200-day average of $3.72, reflecting continued investor caution.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.